Omada Health Inc. (NASDAQ:OMDA) shares are up in Friday’s premarket session following the announcement of its new GLP-1 Flex Care program, which aims to help employers provide access to GLP-1 medications for obesity.

The company on Thursday reported fourth-quarter results that beat expectations and issued upbeat guidance for 2026.

Employer GLP-1 Support

Omada Health’s GLP-1 Flex Care offering enables employers to manage the costs of GLP-1 medications while providing necessary clinical oversight.

The program, announced on Thursday, aims to address the growing demand among employees for these medications, which have seen notable increases in persistence rates among users, with 67% remaining on medication after one year, compared to 47-49% in similar studies.

The initiative is designed to help employers navigate the complexities of medication coverage while ensuring employees receive the necessary support and oversight.

By allowing members to purchase medications independently through cash-pay channels, Omada Health provides a financially sustainable pathway ...